Skip to main content
Top
Published in:

Open Access 09-05-2024 | Type 2 Diabetes | Review

Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects

Authors: Luis A. Vázquez, Santiago Tofé-Povedano, Diego Bellido-Guerrero, Marta Botella-Serrano, Alfonso Soto-González, Pedro Mezquita-Raya, Elías Delgado, Carmen Fajardo-Montañana, Cristóbal Morales-Portillo, Ana Causanilles, Miriam Rubio-de Santos, Irene Romera, Esteban Jódar-Gimeno

Published in: Diabetes Therapy | Issue 7/2024

Login to get access

Abstract

Tirzepatide is a novel antidiabetic medication a single-molecule, agonist to the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. It is approved in the USA and EU for the treatment of type 2 diabetes mellitus (T2DM) and obesity. Due to the potential novelty represented by incorporating tirzepatide to clinical practice, we aim to review practical aspects of tirzepatide use in T2DM and the supporting scientific evidence. A group of ten endocrinologists involved as investigators in the phase 3 SURPASS clinical trial program followed a nominal group technique, a qualitative research methodology designed as a semi-structured group discussion to reach a consensus on the selection of a set of practical aspects. The scientific evidence for tirzepatide has been reviewed with respect to a number of patients’ clinical profiles and care goals. Information of interest related to adverse events, special warnings and precautions, and other considerations for tirzepatide use has been included. Finally, information provided to the patients has been summarized. The practical aspects reported herein may be helpful in guiding physicians in the use of tirzepatide and contribute to optimizing the management of T2DM.
Literature
2.
go back to reference Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules [Internet]. 2022;27(13):4315. Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules [Internet]. 2022;27(13):4315.
3.
go back to reference Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388–96.CrossRefPubMed Thomas MK, Nikooienejad A, Bray R, Cui X, Wilson J, Duffin K, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388–96.CrossRefPubMed
4.
go back to reference Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–55.CrossRefPubMed Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143–55.CrossRefPubMed
5.
go back to reference Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.CrossRefPubMed Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.CrossRefPubMed
6.
go back to reference Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583–98.CrossRefPubMed Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583–98.CrossRefPubMed
7.
go back to reference Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811–24.CrossRefPubMed Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811–24.CrossRefPubMed
8.
go back to reference Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534–45.CrossRefPubMedPubMedCentral Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534–45.CrossRefPubMedPubMedCentral
9.
go back to reference De Block C, Bailey C, Wysham C, Hemmingway A, Allen SE, Peleshok J. Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. Diabetes Obes Metab. 2023;25(1):3–17.CrossRefPubMed De Block C, Bailey C, Wysham C, Hemmingway A, Allen SE, Peleshok J. Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective. Diabetes Obes Metab. 2023;25(1):3–17.CrossRefPubMed
10.
go back to reference Potter M, Gordon S, Hamer P. The nominal group technique: a useful consensus methodology in physiotherapy research. N Z J Physiother. 2004;32:126. Potter M, Gordon S, Hamer P. The nominal group technique: a useful consensus methodology in physiotherapy research. N Z J Physiother. 2004;32:126.
11.
go back to reference Gallagher M, Hares T, Spencer J, Bradshaw C, Webb I. The nominal group technique: a research tool for general practice? Fam Pract. 1993;10(1):76–81.CrossRefPubMed Gallagher M, Hares T, Spencer J, Bradshaw C, Webb I. The nominal group technique: a research tool for general practice? Fam Pract. 1993;10(1):76–81.CrossRefPubMed
12.
go back to reference Moore CM. Applied social research methods series. Group techniques for idea building. Thousand Oaks: Sage Publications; 1987. Moore CM. Applied social research methods series. Group techniques for idea building. Thousand Oaks: Sage Publications; 1987.
13.
go back to reference Tang KC, Davis A. Critical factors in the determination of focus group size. Fam Pract. 1995;12(4):474–5.CrossRefPubMed Tang KC, Davis A. Critical factors in the determination of focus group size. Fam Pract. 1995;12(4):474–5.CrossRefPubMed
14.
go back to reference Leitner DR, Frühbeck G, Yumuk V, Schindler K, Micic D, Woodward E, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies—EASO can lead the way. Obes Facts. 2017;10(5):483–92.CrossRefPubMedPubMedCentral Leitner DR, Frühbeck G, Yumuk V, Schindler K, Micic D, Woodward E, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies—EASO can lead the way. Obes Facts. 2017;10(5):483–92.CrossRefPubMedPubMedCentral
15.
go back to reference Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.CrossRefPubMedPubMedCentral Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753–86.CrossRefPubMedPubMedCentral
16.
go back to reference Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394–405.CrossRefPubMed Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399(10322):394–405.CrossRefPubMed
17.
go back to reference Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88.CrossRefPubMedPubMedCentral Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88.CrossRefPubMedPubMedCentral
18.
go back to reference Boye K, Thieu V, Lee C, Sapin H. Higher weight loss is associated with improved patient reported outcomes in T2D patients treated with tirzepatide. Diabetes Res Clin Pract. 2023;197:110305. Boye K, Thieu V, Lee C, Sapin H. Higher weight loss is associated with improved patient reported outcomes in T2D patients treated with tirzepatide. Diabetes Res Clin Pract. 2023;197:110305.
19.
go back to reference Matza LS, Stewart KD, Landó LF, Patel H, Boye KS. Exit interviews examining the patient experience in clinical trials of tirzepatide for treatment of type 2 diabetes. Patient. 2022;15(3):367–77.CrossRefPubMedPubMedCentral Matza LS, Stewart KD, Landó LF, Patel H, Boye KS. Exit interviews examining the patient experience in clinical trials of tirzepatide for treatment of type 2 diabetes. Patient. 2022;15(3):367–77.CrossRefPubMedPubMedCentral
20.
go back to reference Eli Lilly and Company. Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (SURMOUNT-OSA). ClinicalTrials.gov identifier: NCT05412004. Updated October 23, 2023. Accessed October 26, 2023. https://clinicaltrials.gov/study/NCT05412004. Eli Lilly and Company. Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea (SURMOUNT-OSA). ClinicalTrials.gov identifier: NCT05412004. Updated October 23, 2023. Accessed October 26, 2023. https://​clinicaltrials.​gov/​study/​NCT05412004.
21.
go back to reference Eli Lilly and Company. A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT). ClinicalTrials.gov identifier: NCT04847557. Updated October 23, 2023. Accessed October 26, 2023. https://clinicaltrials.gov/study/NCT04847557. Eli Lilly and Company. A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT). ClinicalTrials.gov identifier: NCT04847557. Updated October 23, 2023. Accessed October 26, 2023. https://​clinicaltrials.​gov/​study/​NCT04847557.
23.
go back to reference Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418–29.CrossRefPubMed Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418–29.CrossRefPubMed
24.
go back to reference Rosenstock J, Frias J, Robdbard H, Tofe S, Sears E, Huh R, et al. 750-P: “SURPASS(ing)” an era of basal-bolus insulin therapy—tirzepatide vs. insulin lispro TID added-on to poorly controlled basal insulin-treated in type 2 diabetes. Diabetes. 2023;72 (Supplement_1):750. Rosenstock J, Frias J, Robdbard H, Tofe S, Sears E, Huh R, et al. 750-P: “SURPASS(ing)” an era of basal-bolus insulin therapy—tirzepatide vs. insulin lispro TID added-on to poorly controlled basal insulin-treated in type 2 diabetes. Diabetes. 2023;72 (Supplement_1):750.
25.
go back to reference Rosenstock J, Vázquez L, Del Prato S, Franco DR, Weerakkody G, Dai B, Landó LF, Bergman BK, Rodríguez A. Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials. Diabetes Care. 2023;46(11):1986–92. https://doi.org/10.2337/dc23-0872 Rosenstock J, Vázquez L, Del Prato S, Franco DR, Weerakkody G, Dai B, Landó LF, Bergman BK, Rodríguez A. Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials. Diabetes Care. 2023;46(11):1986–92. https://​doi.​org/​10.​2337/​dc23-0872
26.
go back to reference Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2018;42(3):416–26.CrossRefPubMedPubMedCentral Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2018;42(3):416–26.CrossRefPubMedPubMedCentral
27.
go back to reference Aleppo G, De Block C, Levine JA, Gomez Valderas E, Benneyworth BD. Glycemic control with tirzepatide in people with type 2 diabetes by baseline HbA1c ≤8.5% or >8.5% (717-P). American Diabetes Association 82nd Scientific Sessions; New Orleans, Louisiana; June 3–7, 2022. Aleppo G, De Block C, Levine JA, Gomez Valderas E, Benneyworth BD. Glycemic control with tirzepatide in people with type 2 diabetes by baseline HbA1c ≤8.5% or >8.5% (717-P). American Diabetes Association 82nd Scientific Sessions; New Orleans, Louisiana; June 3–7, 2022.
28.
go back to reference Kwan A, Ward JM, Gomez Valderas E, Benneyworth BD, Brown K. Efficacy and safety of tirzepatide in people with type 2 diabetes with poor-control baseline HbA1c according to NCQA-HEDIS performance measures: a post hoc analysis of SURPASS-2, SURPASS-3, and SURPASS-4 Academy of Managed Care Pharmacy; March 29–April 1; Chicago, IL. 2022. Kwan A, Ward JM, Gomez Valderas E, Benneyworth BD, Brown K. Efficacy and safety of tirzepatide in people with type 2 diabetes with poor-control baseline HbA1c according to NCQA-HEDIS performance measures: a post hoc analysis of SURPASS-2, SURPASS-3, and SURPASS-4 Academy of Managed Care Pharmacy; March 29–April 1; Chicago, IL. 2022.
29.
go back to reference Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393–406.CrossRefPubMed Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393–406.CrossRefPubMed
30.
go back to reference Eli Lilly and Company. A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT). ClinicalTrials.gov identifier: NCT04255433. Updated October 19, 2023. Accessed January 4, 2024. https://clinicaltrials.gov/ct2/show/NCT04255433. Eli Lilly and Company. A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT). ClinicalTrials.gov identifier: NCT04255433. Updated October 19, 2023. Accessed January 4, 2024. https://​clinicaltrials.​gov/​ct2/​show/​NCT04255433.
31.
go back to reference Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. Endocr Pract. 2023;29(5):305–40.CrossRefPubMed Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of clinical endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. Endocr Pract. 2023;29(5):305–40.CrossRefPubMed
32.
go back to reference Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA(1c) values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care. 2021;44(10):2231–7.CrossRefPubMedPubMedCentral Lind M, Imberg H, Coleman RL, Nerman O, Holman RR. Historical HbA(1c) values may explain the type 2 diabetes legacy effect: UKPDS 88. Diabetes Care. 2021;44(10):2231–7.CrossRefPubMedPubMedCentral
33.
go back to reference Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44.CrossRefPubMed Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633–44.CrossRefPubMed
34.
go back to reference Reyes-García R, Moreno-Pérez Ó, Tejera-Pérez C, Fernández-García D, Bellido-Castañeda V, López de la Torre Casares M, et al. A comprehensive approach to type 2 diabetes mellitus—a recommendation document. Endocrinología, Diabetes y Nutrición (English Ed). 2019;66(7):443–58. Reyes-García R, Moreno-Pérez Ó, Tejera-Pérez C, Fernández-García D, Bellido-Castañeda V, López de la Torre Casares M, et al. A comprehensive approach to type 2 diabetes mellitus—a recommendation document. Endocrinología, Diabetes y Nutrición (English Ed). 2019;66(7):443–58.
35.
go back to reference Małecki MT, Batterham RL, Sattar N, Levine JA, Rodríguez Á, Bergman BK, Wang H, Ghimpeteanu G, Lee CJ. Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4. Diabetes Care. 2023;46(12):2292–99. https://doi.org/10.2337/dc23-1135 Małecki MT, Batterham RL, Sattar N, Levine JA, Rodríguez Á, Bergman BK, Wang H, Ghimpeteanu G, Lee CJ. Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4. Diabetes Care. 2023;46(12):2292–99. https://​doi.​org/​10.​2337/​dc23-1135
36.
go back to reference Hill A. Patient–practitioner communication in diabetes and diabetes-related foot complications. The Diabetic Foot Journal. 2020;23(2):56–61. Hill A. Patient–practitioner communication in diabetes and diabetes-related foot complications. The Diabetic Foot Journal. 2020;23(2):56–61.
37.
go back to reference Linetzky B, Jiang D, Funnell MM, Curtis BH, Polonsky WH. Exploring the role of the patient-physician relationship on insulin adherence and clinical outcomes in type 2 diabetes: Insights from the MOSAIc study. J Diabetes. 2017;9(6):596–605.CrossRefPubMed Linetzky B, Jiang D, Funnell MM, Curtis BH, Polonsky WH. Exploring the role of the patient-physician relationship on insulin adherence and clinical outcomes in type 2 diabetes: Insights from the MOSAIc study. J Diabetes. 2017;9(6):596–605.CrossRefPubMed
38.
go back to reference Pantalone KM, Viljoen A, Galindo RJ, Cui X, Huh R, Fernández Landó L, et al. Patients with type 2 diabetes reach glycemic targets faster with tirzepatide compared to semaglutide and titrated insulin degludec. American Diabetes Association—82nd Annual Scientific Sessions; New Orleans, LA, USA; 3–7 June 2022. Pantalone KM, Viljoen A, Galindo RJ, Cui X, Huh R, Fernández Landó L, et al. Patients with type 2 diabetes reach glycemic targets faster with tirzepatide compared to semaglutide and titrated insulin degludec. American Diabetes Association—82nd Annual Scientific Sessions; New Orleans, LA, USA; 3–7 June 2022.
39.
go back to reference Lingvay I, Giorgino F, Van Gaal LF, Liu M, Rodríguez A, Torcello-Gómez A, et al. Early weight loss and late metabolic outcomes in tirzepatide-treated participants with type 2 diabetes. American Diabetes Association – 83rd Annual Scientific Sessions; 23–26 June San Diego, CA, USA2023. Lingvay I, Giorgino F, Van Gaal LF, Liu M, Rodríguez A, Torcello-Gómez A, et al. Early weight loss and late metabolic outcomes in tirzepatide-treated participants with type 2 diabetes. American Diabetes Association – 83rd Annual Scientific Sessions; 23–26 June San Diego, CA, USA2023.
41.
go back to reference Committee ADAPP. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2021;45(Supplement_1):S185–94. Committee ADAPP. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2021;45(Supplement_1):S185–94.
43.
go back to reference The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.CrossRefPubMedCentral The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.CrossRefPubMedCentral
44.
go back to reference Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591–8.CrossRefPubMedPubMedCentral Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591–8.CrossRefPubMedPubMedCentral
45.
go back to reference Lingvay I, Mosenzon O, Brown K, Cui X, O’Neill C, Fernández Landó L, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol. 2023;22(1):66.CrossRefPubMedPubMedCentral Lingvay I, Mosenzon O, Brown K, Cui X, O’Neill C, Fernández Landó L, et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol. 2023;22(1):66.CrossRefPubMedPubMedCentral
46.
go back to reference Lingvay I, Mosenzon O, Brown K, Cui X, Lando LF, Patel H. 716-P: systolic blood pressure reduction with tirzepatide across SURPASS program: a mediation analysis using weight loss as a factor. Diabetes. 2022;71(Supplement_1):716–51. Lingvay I, Mosenzon O, Brown K, Cui X, Lando LF, Patel H. 716-P: systolic blood pressure reduction with tirzepatide across SURPASS program: a mediation analysis using weight loss as a factor. Diabetes. 2022;71(Supplement_1):716–51.
47.
go back to reference Gomez-Peralta F, Abreu C, Lecube A, Bellido D, Soto A, Morales C, et al. Practical approach to initiating SGLT2 inhibitors in type 2 diabetes. Diabetes Ther. 2017;8(5):953–62.CrossRefPubMedPubMedCentral Gomez-Peralta F, Abreu C, Lecube A, Bellido D, Soto A, Morales C, et al. Practical approach to initiating SGLT2 inhibitors in type 2 diabetes. Diabetes Ther. 2017;8(5):953–62.CrossRefPubMedPubMedCentral
48.
go back to reference Patel H, Khunti K, Rodbard HW, Bajaj HS, Bray R, Kindracki Z, Rodríguez Á. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab. 2024;26(2):473–81. https://doi.org/10.1111/dom.15333 Patel H, Khunti K, Rodbard HW, Bajaj HS, Bray R, Kindracki Z, Rodríguez Á. Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes Obes Metab. 2024;26(2):473–81. https://​doi.​org/​10.​1111/​dom.​15333
49.
go back to reference Reid TS. Practical use of glucagon-like peptide-1 receptor agonist therapy in primary care. Clinical Diabetes. 2013;31(4):148–57.CrossRef Reid TS. Practical use of glucagon-like peptide-1 receptor agonist therapy in primary care. Clinical Diabetes. 2013;31(4):148–57.CrossRef
50.
go back to reference Gray A, Threlkeld RJ. Nutritional Recommendations for Individuals with Diabetes. [Updated 2019 Oct 13]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. Gray A, Threlkeld RJ. Nutritional Recommendations for Individuals with Diabetes. [Updated 2019 Oct 13]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.
51.
go back to reference Gonzalez-Campoy JM, St Jeor ST, Castorino K, Ebrahim A, Hurley D, Jovanovic L, Mechanick JI, Petak SM, Yu YH, Harris KA, Kris-Etherton P, Kushner R, Molini-Blandford M, Nguyen QT, Plodkowski R, Sarwer DB, Thomas KT; American Association of Clinical Endocrinologists; American College of Endocrinology and the Obesity Society. Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society. Endocr Pract. 2013;19 Suppl 3:1–82. https://doi.org/10.4158/EP13155.GL Gonzalez-Campoy JM, St Jeor ST, Castorino K, Ebrahim A, Hurley D, Jovanovic L, Mechanick JI, Petak SM, Yu YH, Harris KA, Kris-Etherton P, Kushner R, Molini-Blandford M, Nguyen QT, Plodkowski R, Sarwer DB, Thomas KT; American Association of Clinical Endocrinologists; American College of Endocrinology and the Obesity Society. Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society. Endocr Pract. 2013;19 Suppl 3:1–82. https://​doi.​org/​10.​4158/​EP13155.​GL
52.
go back to reference Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, Castro A, Cebrián-Cuenca A, de Torres-Sánchez A, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145.CrossRef Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, Castro A, Cebrián-Cuenca A, de Torres-Sánchez A, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145.CrossRef
53.
go back to reference Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical Activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065–79.CrossRefPubMedPubMedCentral Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical Activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016;39(11):2065–79.CrossRefPubMedPubMedCentral
54.
go back to reference Harrington D, Henson J. Physical activity and exercise in the management of type 2 diabetes: where to start? Pract Diabetes. 2021;38(5):35–40b.CrossRef Harrington D, Henson J. Physical activity and exercise in the management of type 2 diabetes: where to start? Pract Diabetes. 2021;38(5):35–40b.CrossRef
Metadata
Title
Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects
Authors
Luis A. Vázquez
Santiago Tofé-Povedano
Diego Bellido-Guerrero
Marta Botella-Serrano
Alfonso Soto-González
Pedro Mezquita-Raya
Elías Delgado
Carmen Fajardo-Montañana
Cristóbal Morales-Portillo
Ana Causanilles
Miriam Rubio-de Santos
Irene Romera
Esteban Jódar-Gimeno
Publication date
09-05-2024
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 7/2024
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-024-01587-6

Other articles of this Issue 7/2024

Diabetes Therapy 7/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare